Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare carcinoma that arises from the breast parenchyma and is entirely composed of squamous cells.
Biomarker and diagnostic research for squamous cell breast carcinoma has been reported in the published literature.
No clinical trials have been registered for squamous cell breast carcinoma.
123 publications have been identified in PubMed for squamous cell breast carcinoma. Research spans Case Report / Case Series (35%), Review / Meta-Analysis (17%), and Epidemiology / Natural History (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 43 | 35% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 6:54 PM UTC
Research summaries
21 |
17% |
Disease patterns and progression | 17 | 14% |
Testing and diagnosis research | 13 | 11% |
Clinical study results | 13 | 11% |
Laboratory research | 13 | 11% |
Other research | 2 | 2% |
New treatment approaches | 1 | 1% |
Al-Eyd G (2026). [PMID: 32491671](https://pubmed.ncbi.nlm.nih.gov/32491671/). *Unknown Journal*. [Diagnostic / Biomarker]
Birungi A (2026). [PMID: 42103938](https://pubmed.ncbi.nlm.nih.gov/42103938/). *Sci Rep*. [Epidemiology / Natural History]
Johnson ML (2026). [PMID: 41926962](https://pubmed.ncbi.nlm.nih.gov/41926962/). *Lancet Oncol*. [Clinical Trial Publication]
Reinking AL (2026). [PMID: 40794189](https://pubmed.ncbi.nlm.nih.gov/40794189/). *Strahlenther Onkol*. [Case Report / Case Series]
Xue L (2026). [PMID: 41603720](https://pubmed.ncbi.nlm.nih.gov/41603720/). *Clin Cancer Res*. [Clinical Trial Publication]
Maloney B (2026). [PMID: 41901361](https://pubmed.ncbi.nlm.nih.gov/41901361/). *Pharmaceuticals (Basel)*. [Basic Science / Preclinical]
Bønløkke S (2026). [PMID: 41589044](https://pubmed.ncbi.nlm.nih.gov/41589044/). *Cancer Med*. [Epidemiology / Natural History]
Liu Q (2026). [PMID: 41852894](https://pubmed.ncbi.nlm.nih.gov/41852894/). *Oncol Lett*. [Case Report / Case Series]
Ahmed H (2026). [PMID: 41675817](https://pubmed.ncbi.nlm.nih.gov/41675817/). *Ann Med Surg (Lond)*. [Case Report / Case Series]
Expert Panel on Breast Imaging (2026). [PMID: 41711626](https://pubmed.ncbi.nlm.nih.gov/41711626/). *J Am Coll Radiol*. [Review / Meta-Analysis]
AI-curated news mentioning squamous cell breast carcinoma
Updated May 25, 2026
A case report and literature review highlight the multimodal imaging evaluation of early-stage metaplastic breast carcinoma with heterologous mesenchymal differentiation. This study contributes to the understanding of imaging techniques in rare breast cancer subtypes.
A case report highlights the long-term response to pembrolizumab in a patient with metastatic metaplastic breast carcinoma. This finding may inform future treatment strategies for this rare breast cancer subtype.